FDA Inspection 1090023 — NeoBiotech Global Corporation

NeoBiotech Global Corporation — FEI 3011869023

The FDA completed an inspection of NeoBiotech Global Corporation on May 13, 2019 in Auburn, WA. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). 8 citations were issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
May 13, 2019
Fiscal Year
2019
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Auburn, WA (United States)

Citations

IDCFRDescription
117721 CFR 211.63Equipment Design, Size and Location
136121 CFR 211.100(a)Absence of Written Procedures
154021 CFR 211.125(a)Strict control not exercised over labeling issued
178721 CFR 211.80(a)Procedures To Be in Writing
188321 CFR 211.165(a)Testing and release for distribution
200921 CFR 211.188Prepared for each batch, include complete information
438921 CFR 211.198(a)Procedures to be written and followed
900121 CFR 211.22(a)Lack of quality control unit